To Download a copy of the presentation click here.
To Download a copy of the Q&A Responses here.
*This call was funded by a cooperative agreement with the Centers for Disease Control and Prevention (grant number NU50CK000574). The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this call does not necessarily represent the policy of CDC or HHS, and should not be considered an endorsement by the Federal Government.
Topic: Antibody Therapy & Second Boosters: Updates and Perspectives on Protecting Our Most Vulnerable
Moderator:
Dana S. Wollins, DrPH, MGC
Vice President, Clinical Affairs & Practice Guidelines, IDSA
Update: New Resources to Manage Paxlovid Drug Interactions
Carlos del Rio, MD, FIDSA
President-Elect, IDSA
Distinguished Professor of Medicine, Division of Infectious Diseases
Emory University School of Medicine
Professor of Epidemiology & Global Health
Rollins School of Public Health of Emory University
Topics and Featured Experts:
Prevention of COVID-19 in Immunocompromised Individuals: Focus on Evusheld
Clinical Considerations & Patient Scenarios
Camille Kotton, MD, FIDSA, FAST
Clinical Director
Transplant & Immunocompromised Host Infectious Diseases
Massachusetts General Hospital
Utilization Update & Strategies to Improve Access
Derek Eisnor, MD
Medical Officer, Division of Clinical Development
Biomedical Advanced Research and Development Authority
COVID-19 Allocation and Distribution Lead
U.S. Department of Health & Human Services
Lessons Learned and Success Stories
Swana K. Thomas, PharmD, MPH
Clinical Pharmacist, Ambulatory Care
Geisinger Health System
Monoclonal Antibody Therapy for Treatment: What are the Options?
Raymund R. Razonable, MD
Professor of Medicine
Vice Chair, Infectious Diseases
Mayo Clinic
Second Boosters: Who Will Benefit?
Updates & Clinical Considerations from the April 20 ACIP Meeting
Elisha Hall, PhD, RD
Lead, Clinical Guidelines
Vaccine Task Force
COVID-19 Response
Centers for Disease Control and Prevention
Perspectives on the Immunocompromised & People Over 50
William Schaffner, MD
Professor of Preventative Medicine, Department of Health Policy
Professor of Medicine, Division of Infectious Diseases
Vanderbilt University School of Medicine
